Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 263846, 11 pages
http://dx.doi.org/10.1155/2013/263846
Research Article

Treatment with CB2 Agonist JWH-133 Reduces Histological Features Associated with Erectile Dysfunction in Hypercholesterolemic Mice

1Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Station 17, BM 5115, CH-1015 Lausanne, Switzerland
2Division of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, 64, Avenue de la Roseraie, 1211 Geneva, Switzerland
3First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, 6 viale Benedetto XV, 16132 Genoa, Italy
4Department of Physiology and Biophysics, Biological Science Institute, Federal University of Minas Gerais, Avenida Antonio Carlos, 6627, 31270-901 Belo Horizonte, MG, Brazil

Received 23 July 2013; Revised 8 September 2013; Accepted 9 September 2013

Academic Editor: Federico Carbone

Copyright © 2013 Rodrigo Araujo Fraga-Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Dean and T. F. Lue, “Physiology of penile erection and pathophysiology of erectile dysfunction,” Urologic Clinics of North America, vol. 32, no. 4, pp. 379–395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Fraga-Silva, F. Montecucco, F. Mach, R. A. Santos, and N. Stergiopulos, “Pathophysiological role of the renin-angiotensin system on erectile dysfunction,” European Journal of Clinical Investigation, vol. 43, no. 9, pp. 978–985, 2013. View at Google Scholar
  3. D. Shin, G. Pregenzer Jr., and J. M. Gardin, “Erectile dysfunction: a disease marker for cardiovascular disease,” Cardiology in Review, vol. 19, no. 1, pp. 5–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. J. Bivalacqua, M. F. Usta, H. C. Champion, P. J. Kadowitz, and W. J. Hellstrom, “Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease,” Journal of Andrology, vol. 24, no. 6, pp. S17–S37, 2003. View at Google Scholar · View at Scopus
  5. B. Musicki, T. Liu, G. A. Lagoda et al., “Hypercholesterolemia-induced erectile dysfunction: endothelial Nitric Oxide Synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase,” The Journal of Sexual Medicine, vol. 7, no. 9, pp. 3023–3032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Kim, M. L. Klyachkin, E. Svendsen, M. G. Davies, P.-O. Hagen, and C. C. Carson III, “Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction,” The Journal of Urology, vol. 151, no. 1, pp. 198–205, 1994. View at Google Scholar · View at Scopus
  7. D. Xie, S. I. Odronic, F. Wu, A. M. Pippen, C. F. Donatucci, and B. H. Annex, “A mouse model of hypercholesterolemia-induced erectile dysfunction,” The Journal of Sexual Medicine, vol. 4, no. 4, part 1, pp. 898–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Nehra, K. M. Azadzoi, R. B. Moreland et al., “Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction,” The Journal of Urology, vol. 159, no. 6, pp. 2229–2236, 1998. View at Google Scholar · View at Scopus
  9. Ç. Yeşilli, Ö. Yaman, and K. Anafarta, “Effect of experimental hypercholesterolemia on cavernosal structures,” Urology, vol. 57, no. 6, pp. 1184–1188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. C. Kim, I. K. Kim, K. K. Seo, K. J. Baek, and M. Y. Lee, “Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits,” Urological Research, vol. 25, no. 5, pp. 341–346, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. K. M. Azadzoi and I. Saenz de Tejada, “Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle,” The Journal of Urology, vol. 146, no. 1, pp. 238–240, 1991. View at Google Scholar · View at Scopus
  12. D. Behr-Roussel, J. Bernabe, S. Compagnie et al., “Distinct mechanisms implicated in atherosclerosis-induced erectile dysfunction in rabbits,” Atherosclerosis, vol. 162, no. 2, pp. 355–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. Kim, K. K. Seo, H. W. Kim, and M. Y. Lee, “The effects if isolated lipoproteins and triglyceride, combined oxidized low density lipoprotein (LDL) plus triglyceride, and combined oxidized LDL plus high density lipoprotein on the contractile and relaxation response of rabbit cavernous smooth muscle,” International Journal of Andrology, vol. 23, supplement 2, pp. 26–29, 2000. View at Google Scholar · View at Scopus
  14. B. Musicki, T. Liu, T. Strong et al., “Low-fat diet and exercise preserve eNOS regulation and endothelial function in the penis of early atherosclerotic pigs: a molecular analysis,” The Journal of Sexual Medicine, vol. 5, no. 3, pp. 552–561, 2008. View at Google Scholar
  15. T. W. Klein, C. Newton, K. Larsen et al., “The cannabinoid system and immune modulation,” Journal of Leukocyte Biology, vol. 74, no. 4, pp. 486–496, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. T. W. Klein, “Cannabinoid-based drugs as anti-inflammatory therapeutics,” Nature Reviews Immunology, vol. 5, no. 5, pp. 400–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Mach, F. Montecucco, and S. Steffens, “Cannabinoid receptors in acute and chronic complications of atherosclerosis,” British Journal of Pharmacology, vol. 153, no. 2, pp. 290–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Steffens, N. R. Veillard, C. Arnaud et al., “Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice,” Nature, vol. 434, no. 7034, pp. 782–786, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Engeli, “Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight,” Handbook of Experimental Pharmacology, vol. 209, pp. 357–381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Lagneux and D. Lamontagne, “Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide,” British Journal of Pharmacology, vol. 132, no. 4, pp. 793–796, 2001. View at Google Scholar · View at Scopus
  21. C. Di Filippo, F. Rossi, S. Rossi, and M. D'Amico, “Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 453–459, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. R. T. Jones, “Cardiovascular system effects of marijuana,” Journal of Clinical Pharmacology, vol. 42, 11, supplement, pp. 58S–63S, 2002. View at Google Scholar · View at Scopus
  23. F. Montecucco, S. Lenglet, V. Braunersreuther et al., “CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 5, pp. 612–620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ghasemi, H. Sadeghipour, and A. R. Dehpour, “Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors,” BJU International, vol. 100, no. 6, pp. 1385–1390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Ghasemi, H. Sadeghipour, A. R. Mani et al., “Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum,” European Journal of Pharmacology, vol. 544, no. 1–3, pp. 138–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. I. M. Vural, G. S. Ozturk, and Y. Sarioglu, “Functional characterization of nonadrenergic noncholinergic neurotransmitter release via endocannabinoids: an in vitro study in rabbit corpus cavernosum,” The Journal of Sexual Medicine, vol. 6, no. 3, pp. 717–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Gratzke, G. J. Christ, C. G. Stief, K.-E. Andersson, and P. Hedlund, “Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity,” European Urology, vol. 57, no. 2, pp. 342–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Montecucco, V. Di Marzo, R. F. da Silva et al., “The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques,” European Heart Journal, vol. 33, no. 7, pp. 846–856, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. A. Fraga-Silva, F. P. Costa-Fraga FP, S. Q. Savergnini et al., “An oral formulation of Angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia,” The Journal of Sexual Medicine, vol. 10, no. 10, pp. 2430–2442, 2013. View at Google Scholar
  30. M. Baumhäkel, F. Custodis, N. Schlimmer, U. Laufs, and M. Böhm, “Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 3, pp. 692–698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Chung, L. De Young, and G. B. Brock, “Investigative models in erectile dysfunction: a state-of-the-art review of current animal models,” The Journal of Sexual Medicine, vol. 8, no. 12, pp. 3291–3305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Jin, G. Lagoda, R. Leite, R. C. Webb, and A. L. Burnett, “NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction,” The Journal of Sexual Medicine, vol. 5, no. 3, pp. 544–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. V. C. Olivon, R. A. Fraga-Silva, D. Segers et al., “Arginase inhibition prevents the low shear stress-induced development of vulnerable atherosclerotic plaques in ApoE-/- mice,” Atherosclerosis, vol. 227, no. 2, pp. 236–243, 2013. View at Google Scholar
  34. K. K. Seo, H.-Y. Yun, H. Kim, and S. C. Kim, “Involvement of endothelial nitric oxide synthase in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbit,” Journal of Andrology, vol. 20, no. 2, pp. 298–306, 1999. View at Google Scholar · View at Scopus
  35. N. F. Gonzalez-Cadavid, “Mechanisms of penile fibrosis,” The Journal of Sexual Medicine, vol. 6, supplement 3, pp. 353–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Basu and B. N. Dittel, “Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease,” Immunologic Research, vol. 51, no. 1, pp. 26–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Julien, P. Grenard, F. Teixeira-Clerc et al., “Antifibrogenic role of the cannabinoid receptor CB2 in the liver,” Gastroenterology, vol. 128, no. 3, pp. 742–755, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. A. Shmist, I. Goncharov, M. Eichler et al., “Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production,” Molecular and Cellular Biochemistry, vol. 283, no. 1-2, pp. 75–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rajesh, P. Mukhopadhyay, G. Haskó, J. W. Huffman, K. Mackie, and P. Pacher, “CB2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration,” British Journal of Pharmacology, vol. 153, no. 2, pp. 347–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Rajesh, P. Mukhopadhyay, S. Bátkai et al., “CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 4, pp. H2210–H2218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Muñoz-Luque, J. Ros, G. Fernández-Varo et al., “Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 2, pp. 475–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Barutta, F. Piscitelli, S. Pinach et al., “Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy,” Diabetes, vol. 60, no. 9, pp. 2386–2396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. D. Johnson, D. L. Phelps, and L. B. Cottler, “The association of sexual dysfunction and substance use among a community epidemiological sample,” Archives of Sexual Behavior, vol. 33, no. 1, pp. 55–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Callen, E. Moreno, P. Barroso-Chinea et al., “Cannabinoid receptors CB1 and CB2 form functional heteromers in brain,” The Journal of Biological Chemistry, vol. 287, no. 25, pp. 20851–20865, 2012. View at Google Scholar
  45. K.-S. C. Marriott and J. W. Huffman, “Recent advances in the development of selective ligands for the cannabinoid CB2 receptor,” Current Topics in Medicinal Chemistry, vol. 8, no. 3, pp. 187–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Molica, C. M. Matter, F. Burger et al., “Cannabinoid receptor CB2 protects against balloon-induced neointima formation,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 5, pp. H1064–H1074, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. R. C. Tostes, F. S. Carneiro, A. J. Lee et al., “Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation,” The Journal of Sexual Medicine, vol. 5, no. 6, pp. 1284–1295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Schlimmer, M. Kratz, M. Böhm, and M. Baumhäkel, “Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis,” British Journal of Pharmacology, vol. 163, no. 4, pp. 804–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Rajesh, S. Bátkai, M. Kechrid et al., “Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy,” Diabetes, vol. 61, no. 3, pp. 716–727, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Montecucco and V. Di Marzo, “At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction,” Trends in Pharmacological Sciences, vol. 33, no. 6, pp. 331–340, 2012. View at Google Scholar
  51. B. Horvth, P. Mukhopadhyay, G. Hask, and P. Pacher, “The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications,” The American Journal of Pathology, vol. 180, no. 2, pp. 432–442, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. B. El-Remessy, M. Rajesh, P. Mukhopadhyay et al., “Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line,” Diabetologia, vol. 54, no. 6, pp. 1567–1578, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Fernández-Ruiz, M. Moreno-Martet, C. Rodríguez-Cueto et al., “Prospects for cannabinoid therapies in basal ganglia disorders,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1365–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Costa and R. Virag, “The endothelial-erectile dysfunction connection: an essential update,” The Journal of Sexual Medicine, vol. 6, no. 9, pp. 2390–2404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. L. Burnett, C. J. Lowenstein, D. S. Bredt, T. S. Chang, and S. H. Snyder, “Nitric oxide: a physiologic mediator of penile erection,” Science, vol. 257, no. 5068, pp. 401–403, 1992. View at Google Scholar · View at Scopus
  56. M. Baumhäkel, N. Schlimmer, K. Büyükafşar, O. Arikan, and M. Böhm, “Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein E-knockout mice,” The Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 818–823, 2008. View at Publisher · View at Google Scholar · View at Scopus